Moderna Inc. (MRNA)
Health Care24 articles
Price chart
Why is MRNA moving?
BullishAug 31In August, several S&P 500 stocks rebounded sharply after facing months of bearish pressures. Moderna (MRNA) saw the highest gain, rising 156% due to promising results for its melanoma vaccine. Other significant winners included Palantir (PLTR) with a 51.45% increase and Veeva Systems (VEEV) at 40.2%. This market recovery is crucial as it highlights the resilience and potential growth in key sectors like biotechnology and enterprise software amid prior investor skepticism.
Read the full story →Moderna Inc. (MRNA) overview
Moderna is a biotech pioneering mRNA vaccines and therapeutics. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Moderna Inc. trades on the NasdaqGS under the ticker symbol MRNA. As of the most recent market data, the stock was priced around $140.34, up 1.70% on the session, giving Moderna Inc. a market capitalization of roughly $56.03B.
Over the past 52 weeks, MRNA has traded between $22.28 and $176.66.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch MRNA
As one of the larger companies in the Health Care sector, Moderna Inc. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch MRNA for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest MRNA news
Moderna (MRNA) Leads August with 156% Gain Amid Market Recovery
In August, several S&P 500 stocks rebounded sharply after facing months of bearish pressures. Moderna (MRNA) saw the highest gain, rising 156% due to promising results for its melanoma vaccine. Other significant winners included Palantir (PLTR) with a 51.45% increase and Veeva Systems (VEEV) at 40.2%. This market recovery is crucial as it highlights the resilience and potential growth in key sectors like biotechnology and enterprise software amid prior investor skepticism.
Read More: Moderna (MRNA) Leads August with 156% Gain Amid Market Recovery
Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
Moderna (MRNA) and Merck (MRK) have reported a breakthrough in developing a cancer vaccine aimed at preventing melanoma recurrence. This is a significant event, marking progress after a century of unsuccessful attempts in cancer vaccine research. The announcement highlights the collaboration between the two companies, potentially impacting their stock performance and investor interest. Investors may want to monitor the developments closely, as advancements in cancer treatment can influence market dynamics and investment strategies in the healthcare sector.
Read More: Moderna (MRNA) and Merck (MRK) Announce Cancer Vaccine Breakthrough
Moderna (MRNA) FDA Approval of Updated COVID-19 Vaccines Confirmed
Moderna (MRNA) has received U.S. FDA approval for its updated COVID-19 vaccines for the 2026-2027 season. The approval comes as COVID-19 cases are reported to be rising, highlighting the ongoing health concerns. This event matters as it indicates continued governmental support for vaccine development amidst health challenges, which could influence market perceptions of Moderna's stock performance. The market impact may hinge on vaccination uptake and public response to the updated vaccines.
Read More: Moderna (MRNA) FDA Approval of Updated COVID-19 Vaccines Confirmed
Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) shares fell 7% to $135.22 after a 392% year-to-date increase, as traders took profits. Despite the decline, the stock has seen significant gains, reaching a record high of $176.66 last week. There were no new negative catalysts reported, and profit-taking appears orderly, with high trading volume noted. The company’s recent phase 3 melanoma trial remains a strong point for investors, as the mRNA therapy's positive data continues to support the bullish sentiment. This decline presents an opportunity for investors to reassess positions in Moderna amidst ongoing developments in its key cancer therapies.
Read More: Moderna (MRNA) Shares Drop 7% After 392% Year-to-Date Surge
Moderna (MRNA) cancer vaccine shows positive breakthrough results
Moderna (MRNA) announced progress in its cancer vaccine trials, reviving interest in biotech ventures. The preliminary data suggests potential efficacy, which may ease concerns over previous performance setbacks. Investors are optimistic this development could lead to an upturn in shares, particularly in a sector still recovering from market volatility. The outcome of these trials may influence future biotech investments, highlighting the importance of innovation in the sector.
Read More: Moderna (MRNA) cancer vaccine shows positive breakthrough results
Moderna (MRNA) mRNA Shot May Change Skin Cancer Treatment Landscape
Moderna's (MRNA) personalized mRNA vaccine for skin cancer is generating significant interest among medical professionals and patients. While some analysts express enthusiasm about its potential, they caution that there may be excessive optimism surrounding this development. The ongoing conversations in the medical community highlight the importance of validating the effectiveness of such treatments before widespread adoption. For investors, the mixed opinions from analysts could indicate volatility in the stock’s performance as market expectations adjust.
Read More: Moderna (MRNA) mRNA Shot May Change Skin Cancer Treatment Landscape
Moderna (MRNA) cancer-vaccine breakthrough drives biopharma rally
Moderna's (MRNA) recent advancements in cancer-vaccine development have contributed to a rally in the biopharmaceutical sector, which has been recovering from a prolonged downturn. The enthusiasm surrounding this breakthrough indicates a growing investor confidence within the industry. Although specific figures were not provided, the overall positive sentiment reflects a shift in market dynamics. This matters for ordinary investors as it signals potential growth opportunities in biopharma stocks, which could be beneficial for their portfolios.
Read More: Moderna (MRNA) cancer-vaccine breakthrough drives biopharma rallyModerna (MRNA) Cancer Vaccine Shows 150% Stock Surge Potential
Merck and Moderna announced promising results from a late-stage trial of their cancer vaccine aimed at preventing melanoma recurrence. The trial demonstrated significant efficacy, contributing to a 150% surge in Moderna's stock price. This notable rise translates into a $5 billion loss for short sellers betting against the stock. The trial results mark a pivotal moment in cancer treatment, impacting market perceptions of both companies' potential in oncology therapeutics. This matters for investors as advancements in medical treatments can significantly influence stock valuations and future revenue streams for companies like Moderna (MRNA).
Read More: Moderna (MRNA) Cancer Vaccine Shows 150% Stock Surge Potential
Moderna (MRNA) Shares Double on Melanoma Vaccine Trial Success
Moderna (MRNA) experienced a doubling in share price following positive outcomes from its late-stage melanoma vaccine trial developed in collaboration with Merck. This development is significant as it indicates potential advancements in cancer treatment and may attract investor interest. The success can impact market perceptions of biotechnology stocks, especially those involved in cancer therapies. Strong results in clinical trials can lead to increased funding and partnership opportunities for Moderna, influencing its future growth potential.
Read More: Moderna (MRNA) Shares Double on Melanoma Vaccine Trial Success
Moderna Soars on Cancer News Amid S&P 500 Gains
The S&P 500 index is experiencing upward momentum as the Federal Reserve's minutes are anticipated. Moderna (MRNA) has responded positively to news regarding progress in cancer treatment. The reception of this news could affect investor confidence and market dynamics going forward. This upward trend in Moderna's stock may attract investor interest amid broader market movements.
Read More: Moderna Soars on Cancer News Amid S&P 500 Gains
Stocks Making Big Moves: Moderna, Pilgrim's Pride, Target
Several companies are experiencing significant stock movements. Moderna shares are moving due to recent developments in its vaccine pipeline, while Pilgrim's Pride is affected by changes in consumer demand. Target's stock reaction stems from recent financial performance reports. This volatility highlights current market trends and investor sentiment, impacting investment strategies for those focused on these companies.
Read More: Stocks Making Big Moves: Moderna, Pilgrim's Pride, TargetModerna (MRNA) cancer vaccine trial shows positive early results
In its first late-stage trial, a personalized cancer vaccine from Moderna (MRNA) and Merck showed positive results. The trial involved over 1,100 patients with higher-risk melanoma and met key goals, significantly extending time until cancer recurrence compared to Keytruda alone. Following the announcement, Merck's stock rose over 8% and Moderna's shares soared about 100%. The trial's success suggests that this combination could be a significant new treatment option for melanoma, impacting future drug development and potential market dynamics for these companies.
Read More: Moderna (MRNA) cancer vaccine trial shows positive early results
Premarket Stock Moves: Zillow, Peloton, Sandisk, Moderna Update
The premarket trading session saw significant movements in multiple stocks. Notable companies included Zillow, Peloton, Sandisk, and Moderna. Details on specific trading volumes or percentage changes were not provided. These movements can impact overall market trends and investor sentiment. Monitoring these fluctuations is important for investors looking to capitalize on premarket activity.
Read More: Premarket Stock Moves: Zillow, Peloton, Sandisk, Moderna Update
Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
Moderna, Inc. (NASDAQ: MRNA) is currently the 12th best-performing stock in the S&P 500, with a year-to-date gain of 146%. Despite this substantial increase, the company is still not profitable and does not expect to reach cash break-even until 2028, with earnings per share expected to turn positive only by 2029. This performance follows a period of stagnation post-COVID. Analysts highlight that while Moderna has promising prospects in cancer trials, investors are advised to wait for a pullback before buying, given the stock's significant rise.
Read More: Moderna (MRNA) Stock Up 146% Year to Date Amid Market Rotation
Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
In FY 2025, Moderna (MRNA) reported revenue exceeding $1.9 billion, a 40% decrease from the prior year, alongside a net loss of approximately $2.8 billion. The company's debt-to-equity ratio was about 0.2x, and free cash flow was nearly $2.1 billion negative. In comparison, Recursion Pharmaceuticals (RXRX) generated approximately $74.7 million in revenue, marking a 27% year-over-year increase, but recorded a net loss of nearly $645 million. Its debt-to-equity ratio stood at around 0.1x, with free cash flow of about negative $378 million, indicating significant investment in its infrastructure.
Read More: Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
Moderna (MRNA) and ON Semiconductor (ON) Notable Market Moves Today
Moderna (MRNA) and ON Semiconductor (ON) were highlighted among stocks making significant midday moves. Although the article mentions several companies, specific data points, metrics, or trading volumes are not provided regarding these stock movements. Such notable movements can impact investor sentiment and potential trading strategies. Without verifiable events or figures, the overall market implications remain unclear.
Read More: Moderna (MRNA) and ON Semiconductor (ON) Notable Market Moves Today
Moderna (MRNA) FDA Committee Recommends First mRNA Flu Vaccine
A key FDA advisory panel has unanimously recommended Moderna's (MRNA) mRNA flu vaccine, marking the first of its kind since 2023. This recommendation is significant as it could pave the way for regulatory approval, enhancing Moderna's portfolio and potentially impacting market positioning against competitors. The vaccine is designed specifically for older adults, addressing a critical healthcare need. The panel's endorsement follows discussions regarding the vaccine's efficacy and safety, which may influence investor sentiment in the biopharmaceutical sector.
Read More: Moderna (MRNA) FDA Committee Recommends First mRNA Flu Vaccine
Moderna (MRNA) Receives Unanimous FDA Panel Approval for mRNA Vaccine
The FDA advisory panel voted unanimously to approve Moderna's (MRNA) mRNA flu vaccine for older adults. This decision may impact the market by potentially increasing demand for Moderna's vaccine offerings. The mRNA flu vaccine is expected to enhance B cell response breadth in humans, a factor that could improve public health outcomes. The approval comes after prior controversies surrounding the vaccine's deployment, adding weight to the FDA's endorsement.
Read More: Moderna (MRNA) Receives Unanimous FDA Panel Approval for mRNA Vaccine
Moderna (MRNA) Stock Breakout Amid Market Reactions to Iran Deal
Moderna (MRNA) experienced significant stock movement following news of a peace deal in Iran, which positively influenced market sentiment. This development contributed to a rise in the Dow Jones Industrial Average, further supported by bullish trends in AI stocks. The market is observing a shift in trading volumes, but specific numbers were not detailed. Overall, the implications of the Iran agreement on broader market conditions may indicate increased investor confidence.
Read More: Moderna (MRNA) Stock Breakout Amid Market Reactions to Iran Deal
Moderna (MRNA) Form 144 Filed on June 15 Reveals Insider Activity
On June 15, Moderna (MRNA) filed Form 144, a document indicating the intention to sell shares of its common stock. This filing reflects potential insider selling, which can impact investor sentiment and market perceptions. Understanding the volume and timing of these sales is crucial for assessing the company's stock performance. The details of shares sold or the significance of this transaction will be closely monitored by investors for any potential effects on MRNA's market behavior.
Read More: Moderna (MRNA) Form 144 Filed on June 15 Reveals Insider Activity
Moderna (MRNA) to Review Flu Vaccine at FDA Expert Committee Meeting
The US FDA announced it will hold a meeting with an expert committee to review the flu vaccine developed by Moderna (MRNA). This meeting is crucial as it will assess the vaccine's efficacy and safety. Given the increasing interest in flu vaccinations, particularly in the context of ongoing health concerns, this evaluation may impact market perception of Moderna's future revenues. The outcome of the review could influence both Moderna's stock performance and broader market trends in the biotech sector.
Read More: Moderna (MRNA) to Review Flu Vaccine at FDA Expert Committee Meeting
Moderna (MRNA) faces profitability test amid revenue challenges
Moderna (MRNA) is currently under scrutiny regarding its profitability as the company's revenue streams face challenges. The latest reports indicate a significant decrease in demand for its COVID-19 vaccine, leading to a projected revenue drop of 70% for 2023 compared to 2022. Given these developments, experts are closely monitoring MRNA's financial stability and operational adjustments. The ongoing analysis could impact the biotech sector as investors evaluate the company's future prospects.
Read More: Moderna (MRNA) faces profitability test amid revenue challenges
Moderna (MRNA) and Other Stocks Movements Seen in Premarket
Several stocks, including Moderna (MRNA), Lumentum, Intel, and monday.com, are experiencing notable movements in premarket trading. However, concrete data points such as trading volumes or percentage changes have not been reported in this article. The market impact of these movements remains unclear due to the lack of specific figures or insights into the reasons behind the fluctuations. Monitoring these stocks could provide insights into broader market trends and investor sentiment.
Read More: Moderna (MRNA) and Other Stocks Movements Seen in Premarket
Moderna (MRNA) and Pharma Stocks Surge Amid Hantavirus Concerns
Following the World Health Organization's announcement of a hantavirus outbreak on May 2, several pharmaceutical stocks, including Moderna (MRNA), experienced significant gains. Moderna's shares increased by 7% in premarket trading as the company is conducting preclinical research on the hantavirus. Inovio Pharmaceuticals reported a 13% rise, while Emergent Biosolutions and Novavax gained 4% and 3%, respectively. Analysts from Evercore ISI suggested that any revenue potential for Moderna related to hantavirus is unlikely, viewing stock movements as sentiment-driven rather than fundamentally driven.
Read More: Moderna (MRNA) and Pharma Stocks Surge Amid Hantavirus ConcernsMore Health Care stocks
Frequently asked questions
Is Moderna Inc. in the S&P 500?
Yes. Moderna Inc. (MRNA) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is MRNA in?
Moderna Inc. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest MRNA news?
This page collects recent Moderna Inc. (MRNA) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Moderna Inc.'s stock price?
As of the most recent market data, Moderna Inc. (MRNA) traded at approximately $140.34. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Moderna Inc.'s market cap?
Moderna Inc. has a market capitalization of roughly $56.03B, based on its most recent share price and shares outstanding.